Herbal and alternative approaches to obesity

Handbook of Obesity: Clinical Applications

Volumn , Issue , 2003, Pages 329-358

  Greenway, Frank L ^a,b   Heber, David ^c,d  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 8344286475     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (269)

1. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343:1833-1838.
2. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 1999; 58:807-810.
3. Malchow-Moller A, Larsen S, Hey H, Stokholm KH, Juhl E, Quaade F. Ephedrine as an anorectic: the story of the “Elsinore pill”. Int J Obes 1981; 5:183-187.
4. Goodman L, Gilman A. The Pharmacological Basis of Therapeutics, 7 ed. New York: Macmillan, 1985.
5. Miller DS. A controlled trial using ephedrine in the treatment of obesity [letter]. Int J Obes 1986; 10:159-160.
6. Drug Topics Red Book Montvale, NJ: Medical Economics Company, 2000.
7. Macdonald IA. Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes Relat Metab Disord 1995; 19(suppl 7):S2-S7.
8. Chen MD, Lin WH, Song YM, Lin PY, Ho LT. Effect of caffeine on the levels of brain serotonin and catecholamine in the genetically obese mice. Chung Hua I Hsueh Tsa Chih (Taipei) 1994; 53:257-261.
9. Oberman Z, Herzberg M, Jaskolka H, Harell A, Hoerer E, Laurian L. Changes in plasma cortisol, glucose and free fatty acids after caffeine ingestion in obese women. Isr J Med Sci 1975; 11:33-36.
10. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jequier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr 1980; 33:989-997.
11. Jung RT, Shetty PS, James WP, Barrand MA, Callingham BA. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. Clin Sci 1981; 60:527-535.
12. Dulloo AG, Geissler CA, Horton T, Collins A, Miller DS. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr 1989; 49:44-50.
13. Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. Am J Physiol 1995; 269:E671-E678.
14. Bondi M, Grugni G, Velardo A, et al. Adrenomedullary response to caffeine in prepubertal and pubertal obese subjects. Int J Obes Relat Metab Disord 1999; 23:992-996.
15. Tagliabue A, Terracina D, Cena H, Turconi G, Lanzola E, Montomoli C. Coffee induced thermogenesis and skin temperature. Int J Obes Relat Metab Disord 1994; 18:537-541.
16. Yoshida T, Sakane N, Umekawa T, Kondo M. Relationship between basal metabolic rate, thermogenic response to caffeine, and body weight loss following combined low calorie and exercise treatment in obese women. Int J Obes Relat Metab Disord 1994; 18:345-350.
17. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Br J Clin Pharmacol 1985; 20:61-66.
18. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993; 25:103-114.
19. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes Relat Metab Disord 1995; 19:234-239.
20. Haffner SM, Knapp JA, Stern MP, Hazuda HP, Rosenthal M, Franco LJ. Coffee consumption, diet, and lipids. Am J Epidemiol 1985; 122:1-12.
21. La Vecchia C, Franceschi S, Decarli A, Pampallona S, Tognoni G. Risk factors for myocardial infarction in young women. Am J Epidemiol 1987; 125:832-843.
22. Toner JM, Close CF, Ramsay LE. Factors related to treatment resistance in hypertension. Q J Med 1990; 77: 1195-1204.
23. Ohayon MM, Guilleminault C, Priest RG, Caulet M. Snoring and breathing pauses during sleep: telephone interview survey of a United Kingdom population sample [see comments]. BMI 1997; 314:860-863.
24. Gartside PS, Glueck CJ. Relationship of dietary intake to hospital admission for coronary heart and vascular disease: the NHANES If national probability study. J Am Coll Nutr 1993; 12:676-684.
25. Stamler J, Caggiula A, Grandits GA, Kjelsberg M, Cutler JA. Relationship to blood pressure of combinations of dietary macronutrients. Findings of the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 1996; 94:2417-2423.
26. Wakabayashi K, Kono S, Shinchi K, et al. Habitual coffee consumption and blood pressure: a study of self-defense officials in Japan. Eur J Epidemiol 1998; 14:669-673.
27. Noble R. A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine. Drug Intell Clin Pharm 1988; 22:296-299.
28. Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo Study. JAMA 1994; 271:280-283.
29. Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995; 49:37-50.
30. Ramadan NM. Headache caused by raised intracranial pressure and intracranial hypotension. Curr Opin Neurol 1996; 9:214-218.
31. Massoudi M. Miller DS. Ephedrine, a thermogenic and potential slimming drug. ProcNutr Soc 1977; 36:135A.
32. Yen TT, McKee MM, Bemis KG. Ephedrine reduces weight of viable yellow obese mice (Avy/a). Life Sci 1981; 28:119-128.
33. Wilson S. Arch JR, Thurlby PL. Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Life Sci 1984; 35:1301-1309.
34. Massoudi M, Evans E. Miller DS. Thermogenic drugs for the treatment of obesity: screening using obese rats and mice. Ann Nutr Metab 1983; 27:26-37.
35. Dulloo AG, Miller DS. Thermogenic drugs for the treatment of obesity: sympathetic stimulants in animal models. Br J Nutr 1984; 52:179-196.
36. Liu YL. Toubro S, Astrup A, Stock M. Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int I Obes Relat Metab Disord 1995; 19:678-685.
37. Bukowiecki L, Jahjah L, Follea N. Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via beta-adrenoreceptors. Int J Obes 1982; 6:343-350.
38. Bailey CJ, Thornburn CC, Flatt PR. Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. Gen Pharmacol 1986; 17:243-246.
39. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis; potential use in the treatment of obesity. Am J Clin Nutr 1987; 45:564-569.
40. Sapeika N. Drugs in obesity. S Afr Med J 1974; 48:2027-2030.
41. Astrup A, Lundsgaard C, Madsen J, Christensen NJ. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am J Clin Nutr 1985; 42:83-94.
42. Astrup A, Madsen J, Hoist JJ, Christensen NJ. The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. Metabolism 1986; 35:260-265.
43. Pasquali R, Baraldi G, Cesari MP, et al. A controlled trial using ephedrine in the treatment of obesity. Int J Obes 1985; 9:93-98.
44. Pasquali R, Cesari MP, Besteghi L, Melchionda N, Balestra V. Thermogenic agents in the treatment of human obesity: preliminary results. Int J Obes 1987; 11:23-26.
45. Pasquali R, Cesari MP, Melchionda N, Stefanini C. Raitano A, Labo G. Does ephedrine promote weight loss in low-energy-adapted obese women? Int J Obes 1987; 11:163-168.
46. Pasquali R, Casimirri F. Melchionda N, et al. Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin Sci (Colch) 1992; 82:85-92.
47. Nielsen B, Astrup A, Samuelsen P, Wengholt H. Christensen NJ. Effect of physical training on thermogenic responses to cold and ephedrine in obesity. Int J Obes Relat Metab Disord 1993; 17:383-390.
48. Astrup A. Thermogenesis in human brown adipose tissue and skeletal muscle induced by sympathomimetic stimulation. Acta Endocrinol Suppl 1986; 278:1-32.
49. Jonderko K, Kucio C. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. Aliment Pharmacol Ther 1991; 5:413-418.
50. Jaedig S. Henningsen NC. Increased metabolic rate in obese women after ingestion of potassium, magnesium-and phosphate-enriched orange juice or injection of ephedrine. Int J Obes 1991; 15:429-436.
51. Horton TJ, Geissler CA. Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women. Int J Obes 1991; 15:359-366.
52. Geissler CA. Effects of weight loss, ephedrine and aspirin on energy expenditure in obese women. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S45-S48.
53. Pasquali R, Casimirri F. Clinical aspects of ephedrine in the treatment of obesity. Int J Obes RelatMetab Disord 1993; 17(suppl 1):S65-S68.
54. Dvorak R, Starling RD, Calles-Escandon J, Sims EA, Poehlman ET. Drug therapy for obesity in the elderly. Drugs Aging 1997; 11:338-351.
55. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: animal studies. Am J Clin Nutr 1986; 43:388-394.
56. Dulloo AG, Miller DS. Reversal of obesity in the genetically obese fa/fa Zucker rat with an ephedrine’ methylxanthines thermogenic mixture. J Nutr 1987; 117:383-389.
57. Tulp OL, Buck CL. Caffeine and ephedrine stimulated thermogenesis in LA-corpulent rats. Comp Biochem Physiol C 1986; 85:17-19.
58. Dulloo AG. Miller DS. Prevention of genetic fa/fa obesity with an ephedrine-methylxanthines thermogenic mixture. Am J Physiol 1987; 252:R507-R513.
59. Ramsey JJ, Colman RJ, Swick AG, Kemnitz JW. Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. Am J Clin Nutr 1998; 68:42-51.
60. Lowell BB, Napolitano A. Usher P, et al. Reduced adipsin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine. Endocrinology 1990; 126:1514-1520.
61. Napolitano A, Lowell BB, Flier JS. Alterations in sympathetic nervous system activity do not regulate adipsin gene expression in mice. Int J Obes 1991; 15:227-235.
62. Spurlock ME, Hahn KJ, Miner JL. Regulation of adipsin and body composition in the monosodium glutamate (MSG)-treated mouse. Physiol Behav 1996; 60:1217-1221.
63. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism 1992; 41:1233-1241.
64. Malecka-Tendera E. Effect of ephedrine and theophylline on weight loss, resting energy expenditure and lipoprotein lipase activity in obese over-fed rats. Int J Obes Relat Metab Disord 1993; 17:343-347.
65. Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Rondo M. Thermogenic, anti-obesity effects of bofu-tsusho-san in MSG-obese mice. Int J Obes Relat Metab Disord 1995; 19:717-722.
66. Han LK, Takaku T. Li J. Kimura Y, Okuda H. Anti-obesity action of oolong tea. Int J Obes Relat Metab Disord 1999; 23:98-105.
67. Dulloo AG, Seydoux J, Girardier L, Chantre P, Van-dermander J. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. Int J Obes Relat Metab Disord 2000; 24:252-258.
68. Stokholm KH, Hansen MS. Lowering of serum total T3 during a conventional slimming regime. Int J Obes 1983; 7:195-199.
69. Dulloo AG. Miller DS. The thermogenic properties of ephedrine/methy[xanthine mixtures: human studies. Int J Obes 1986; 10:467-481.
70. Krieger DR. Daly PA, Dulloo AG. Ransil BJ. Young JB, Landsberg L. Ephedrine, caffeine and aspirin promote weight loss in obese subjects. Trans Assoc Am Physicians 1990; 103:307-312.
71. Astrup A. Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 1991; 40:323-329.
72. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992; 16:269-277.
73. Toubro S, Astrup A. Breum L, Quaade F. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int J Obes Relat Metab Disord 1993; 17(suppl 3):S73-S77; discussion S82.
74. Astrup A, Toubro S, Christensen NJ. Quaade F. Pharmacology of thermogenic drugs. Am J Clin Nutr 1992: 55246S-248S.
75. Astrup A. Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S41-S43.
76. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S73-S78.
77. Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992;41:686-688.
78. Buemann B, Marckmann P. Christensen NJ, Astrup A, The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 mJ/day diet. Int J Obes Relat Metab Disord 1994; 18:329-332.
79. Molnar D. Effects of ephedrine and aminophylline on resting energy expenditure in obese adolescents. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S49-S52.
80. Molnar D, Torok K, Erhardt E. Jeges S. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 2000; 24:1573-1578.
81. Atkinson RL. Blank RC, Loper JF, Schumacher D, Lutes RA. Combined drug treatment of obesity. Obes Res 1995; 3(suppl 4):497S-500S.
82. Breum L, Pcdersen JK, Ahlstrom F, Frimodt-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord 1994; 18:99-103.
83. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999; 7:523-531.
84. Waluga M. Janusz M, Karpel E, Hartleb M. Nowak A. Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women. Clin Physiol 1998; 18:69-76.
85. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999; 70:1040-1045.
86. Norregaard J, Jorgensen S, Mikkelsen KL, et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. Clin Pharmacol Ther 1996; 60:679-686.
87. Svendsen TL, Lngerslev J, Mork A. Is Letigen contra-indicated in hypertension? A double-blind, placebo controlled multipractice study of Letigen administered to normotensive and adequately treated patients with hypersensitivity. Ugeskr Laeger 1998; 160:4073-4075.
88. Altschuler S, Conte A, Sebok M, Marlin RL. Winick C. Three controlled trials of weight loss with phenylpropanolamine. Int J Obes 1982; 6:549-556.
89. Greenway FL. Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr 1992; 55:203S-205S.
90. Jequier E, Energy utilization in human obesity. Ann NY Acad Sci 1987: 499:73-83.
91. Drew R. Nonprescription appetite suppressants. N C Med J 1983; 44:573-574.
92. Zgourides GD, Warren R, Englert ME. Ephedrine-induced thermogenesis as an adjunct to cognitive restructuring and covert conditioning: a proposal for treatment of obese individuals. Percept Mot Skills 1989; 69:563-572.
93. Egger G. Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements [see comments]. Med J Aust 1999; 171:604-608.
94. Poston WS 2d, Foreyt JP, Borrell L, Haddock CK. Challenges in obesity management [see comments]. South Med J 1998; 91:710-720.
95. Doucet E. Tremblay A. Food intake, energy balance and body weight control. Eur J Clin Nutr 1997; 51:846-855.
96. Dulloo AG, Stock MJ. Ephedrine in the treatment of obesity [editorial]. Int J Obes Relat Metab Disord 1993; 17(suppl I):S1-S2.
97. Ryan DH. Medicating the obese patient. Endocrinol Metab Clin North Am 1996; 25:989-1004.
98. Davis R, Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 1996; 52:696-724.
99. Finer N. Present and future pharmacological approaches. Br Med Bull 1997; 53:409-432.
100. Carek PJ, Dickerson LM. Current concepts in the pharmacological management of obesity. Drugs 1999; 57:883-904.
101. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20:805-875.
102. Bray GA. Drug treatment of obesity. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13:131-148.
103. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes 1998; 106:29-34.
104. Astrup AV. Treatment of obesity with thermogenic agents [editorial]. Nutrition 1989; 5:70.
105. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: “over-the-counter” drugs that interact to stimulate thermogenesis in the obese. Nutrition 1989; 5:7-9.
106. Dullo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S35-S40.
107. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res 1995; 3(suppl 4):537S-540S.
108. Astrup A, Breum L, Toubro S, Hein P, Quaade F. Ephedrine and weight loss. Int J Obes Relat Metab Disord 1992; 16:715.
109. Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects1 weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. Bmj 1997; 314:29-34.
110. Sesso HD, Gaziano JM, Buring JE. Hennekens CH. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999; 149:162-167.
111. Borchardt RT, Huber JA. Catechol O-methyltransfer-ase. 5. Structure-activity relationships for inhibition by flavonoids. J Med Chem 1975; 18:120-122.
112. Dulloo AG, Seydoux J, Giradier L. Tealine and thermogenesis: interactions between polyphenols, caffeine and sympathetic activity. Int J Obes Relat Metab Disord 1996; 20(suppl 4):71.
113. Han LK, Takaku T, Li J, Kimura Y. Okuda H. Anti-obesity action of oolong tea. Int J Obes Relat Metab Disord 1999; 23:98-105.
114. Colker C, Kalman D, Torina G, Pedis T, Street C. Effects of citrus aurantium extract, caffeine and St. John’s wort on body fat loss, lipid levels and mood state in overweight healthy adults. Curr Ther Res 1999; 60:145-153.
115. Henry CJ, Emery B. Effect of spiced food on metabolic rate. Hum Nutr Clin Nutr 1986; 40:165-168.
116. Yoshioka M, St-Pierre S, Suzuki M, Tremblay A. Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women. Br J Nutr 1998; 80:503-510.
117. Choi Y, Kim YC, Han YB, Park Y, Pariza MW, Ntambi JM. The Irans-I0, cis-12 isomer of conjugated linoleic acid downregulates stearoyl-CoA desaturase I gene expression in 3T3-L1 adipocytes. J Nutr 2000; 130:1920-1924.
118. Griinari JM. Corl BA. Lacy SH. Chouinard PY, Nur-mela KV, Bauman DE. Conjugated linoleic acid is synthesized endogenously in lactating dairy cows by delta(9)-desaturase. J Nutr 2000; 130:2285-2291.
119. Dhiman TR, Satter LD, Pariza MW, Galli MP, Albright K, Tolosa MX. Conjugated linoleic acid (CLA) content of milk from cows offered diets rich in linoleic and linolenic acid. J Dairy Sci 2000; 83:1016-1027.
120. Kritchevsky D, Antimutagenic and some other effects of conjugated linoleic acid. Br J Nutr 2000; 83:459-465.
121. MacDonald HB. Conjugated linoleic acid and disease prevention: a review of current knowledge. J Am Coll Nutr 2000; 19:111S-118S.
122. Pariza MW. Park Y, Cook ME. Conjugated linoleic acid and the control of cancer and obesity. Toxicol Sci 1999; 52:107-110.
123. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-\0, cis-\2 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 1999; 34:235-241.
124. Park Y. Albright KJ, Liu W, Storkson JM, Cook ME. Pariza MW. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997; 32:853-858.
125. West DB, Delany JP, Camet PM, Blohm F, Truett AA. Scimeca J. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998; 275:R667-R672.
126. DeLany JP, Blohm F, Truett A A, Scimeca JA, West DB. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol 1999; 276: R1172-R1179.
127. Yamasaki M, Mansho K. Mishima H, el al. Dietary effect of conjugated linoleic acid on lipid levels in white adipose tissue of Sprague-Dawley rats. Biosci Biotech-nol Biochem 1999; 63.1104-1106.
128. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, et al. Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 2000; 49:1534-1542.
129. Satory DL, Smith SB. Conjugated linoleic acid inhibits proliferation but stimulates lipid filling of murine 3T3-Ll preadipocytes. J Nutr 1999; 129:92-97.
130. Azain MJ, Hausman DB. Sisk MB, Flatt WP, Jewell DE. Dietary conjugated linoleic acid reduces rat adipose tissue cell size rather than cell number. J Nutr 2000; 130:1548-1554.
131. Sullivan C, Triscari J. Metabolic regulation asa control for lipid disorders. I, Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent. Am J Clin Nutr 1977; 30:767-776.
132. Badmaev V, Majeed M. Open field, physician-controlled clinical evaluation of botanical weight loss formula citrin. Nulracon 1995: nutraceuticals, dietary supplements and functional foods. Las Vegas, July 1113, 1995.
133. Kriketos AD. Thompson HR, Greene H, Hill JO. Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state. Int J Obes Relat Metab Disord 1999; 23:867-873.
134. Heymsfield SB, Allison DB, Vasselli JR. Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998; 280:1596-1600.
135. Clore JN. Dehydroepiandrosterone and body fat. Obes Res 1995; 3(suppl 4):613S-616S.
136. Abrahamsson L, Hackl H. Catabolic effects and the influence on hormonal variables under treatment with Gynodian-Depot or dehydroepiandrosterone (DHEA) oenanthate. Maturitas 1981; 3:225-234.
137. Nestler JE. Barlascini CO, Clore JN. Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66:57-61.
138. Mortola JF. Yen SS, The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71:696-704.
139. Usiskin KS, Butterworth S. Clore JN. et al. Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 1990; 14:457-463.
140. Welle S, Jozefowicz R. Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab 1990; 71:1259-1264.
141. Morales A J, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78:1360-1367.
142. Morales AJ, Haubrich RH, Hwang JY. Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49:421-432.
143. Porter DJ, Raymond LW. Anastasio GD. Chromium: friend or foe? Arch Fam Med 1999; 8:386-390.
144. Page TG, Southern LL, Ward TL, Thompson DL Jr. Effect of chromium picolinate on growth and serum and carcass traits of growing-finishing pigs. J Anim Sci 1993:71:656-662.
145. Mooney KW, Cromwell GL. Efficacy of chromium picolinate and chromium chloride as potential carcass modifiers in swine. J Anim Sci 1997; 75:2661-2671.
146. Mooney KW, Cromwell GL. Effects of dietary chromium picolinate supplementation on growth, carcass characteristics, and accretion rates of carcass tissues in growing-finishing swine. J Anim Sci 1995; 73:3351-3357.
147. Lindemann MD, Wood CM, Harper AF, Kornegay ET, Anderson RA. Dietary chromium picolinate additions improve gain: feed and carcass characteristics in growing-finishing pigs and increase litter size in reproducing sows. J Anim Sci 1995; 73:457-465.
148. Boleman SL. Boleman SJ. Bidner TD. et al. Effect of chromium picolinate on growth, body composition, and tissue accretion in pigs. J Anim Sci 1995; 73:2033-2042.
149. Myers MJ, Farrell DE. Evock-Clover CM, Cope CV, Henderson M, Steele NC. Effect of recombinant growth hormone and chromium picolinate on cytokine production and growth performance in swine. Pathobiol-ogy 1995; 63:283-287.
150. Evock-Clover CM, Polansky MM, Anderson RA, Steele NC. Dietary chromium supplementation with or without somatotropin treatment alters serum hormones and metabolites in growing pigs without affecting growth performance. J Nutr 1993; 123:1504-1512.
151. Bunting LD. Fernandez JM. Thompson DL Jr, Southern LL. Influence of chromium picolinate on glucose usage and metabolic criteria in growing Holstein calves. J Anim Sci 1994; 72:1591-1599.
152. Hasten DL, Rome EP, Franks BD, Hegsted M. Effect of chromium picolinate on beginning weight training students. Int J Sport Nutr 1992; 2:343-350.
153. Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc 1997; 29:992-998.
154. Clancy SP, Clarkson PM. DeCheke ME, etal. Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. Int J Sport Nutr 1994; 4:142-153.
155. Trent LK, Thieding-Cancel D. Effects of chromium picolinate on body composition. J Sports Med Phys Fitness 1995; 35:273-280.
156. Lukaski HC, Bolonchuk WW, Siders WA, Milne DB. Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men [see comments]. Am J Clin Nutr 1996; 63:954-965.
157. Bahadori B. Wallner S. Schneider H, Wascher TC, Toplak H. Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet. Acta Med Austriaca 1997;24:185-187.
158. Pasman WJ, Westerterp-Plantenga MS, Saris WH. The effectiveness of long-term supplementation of carbohydrate, chromium, fibre and caffeine on weight maintenance. Int J Obes Relat Metab Disord 1997; 21:1143-1151.
159. Walker LS, Bemben MG, Bemben DA, Knehans AW. Chromium picolinate effects on body composition and muscular performance in wrestlers. Med Sci Sports Exerc 1998; 30:1730-1737.
160. Campbell WW, Joseph LJ, Davey SL, Cyr-Campbell D, Anderson RA, Evans WJ. Effects of resistance training and chromium picolinate on body composition and skeletal muscle in older men. J Appl Physiol 1999; 86:29-39.
161. Press Rl. Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects [see comments]. West J Med 1990; 152:41-45.
162. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on scrum triglyceride levels in NIDDM. Diabetes Care 1994; 17:1449-1452.
163. Preuss HG, Grojec PL, Lieberman S, Anderson RA. Effects of different chromium compounds on blood pressure and lipid peroxidation in spontaneously hypertensive rats. Clin Nephrol 1997; 47:325-330.
164. Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr 1997; 16:404-410.
165. Anderson RA, Cheng N, Bryden NA. Polansky MM, Chi J, Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46:1786-1791.
166. Evans GW, Bowman TD. Chromium picolinate increases membrane fluidity and rate of insulin internalization. J Inorg Biochem 1992; 46:243-250.
167. Stearns DM, Wise JP Sr, Patierno SR. Wetterhahn KE. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J 1995; 9:1643-1648.
168. Stearns DM, Belbruno JJ, Wetterhahn KE. A prediction of chromium (III) accumulation in humans from chromium dietary supplements. FASEB J 1995; 9:1650-1657.
169. Anderson RA, Bryden NA, Polansky MM. Lack of toxicity of chromium chloride and chromium picolinate in rats. J Am Coll Nutr 1997; 16:273-279.
170. Vincent JB. The biochemistry of chromium. J Nutr 2000; 130:715-718.
171. Nissen S, Sharp R, Ray M, et al. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol 1996; 81:2095-2104.
172. Kreider RB, Ferreira M, Wilson M, Almada AL. Effects of calcium beta-hydroxy-beta-methylbutyrate (HMB) supplementation during resistance-training on markers of catabolism, body composition and strength. Int J Sports Med 1999; 20:503-509.
173. Nissen S, Sharp RL, Panton L, Vukovich M, Trappe S, Fuller JC. Beta-hydroxy-beta-methylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors. J Nutr 2000; 130:1937-1945.
174. Ronsard N. Cellulite: Those Lumps, Bumps, and Bulges You Couldn’t Lose Before. New York: Beauty and Health Publishing Co., 1973.
175. Arner P. Adrenergic receptor function in fat cells. Am J Clin Nutr 1992; 55:228S-236S.
176. Arner P, Hellstrom L, Wahrenberg H, Bronnegard M. Beta-adrenoceptor expression in human fat cells from different regions. J Clin Invest 1990; 86:1595-1600.
177. Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993; 34:1057-1091.
178. Presta E, Leibel RL, Hirsch J. Regional changes in adrenergic receptor status during hypocaloric intake do not predict changes in adipocyte size or body shape. Metabolism 1990; 39:307-315.
179. Vernon RG. Effects of diet on lipolysis and its regulation. Proc Nutr Soc 1992; 51:397-408.
180. Greenway FL. Bray GA. Regional fat loss from the thigh in obese women after adrenergic modulation. Clin Ther 1987; 9:663-669.
181. Greenway FL, Bray GA, Heber D. Topical fat reduction. Obes Res 1995; 3(suppl 4):561S-568S.
182. Collis N, Elliot LA, Sharpe C, Sharpe DT. Cellulite treatment: a myth or reality: a prospective randomized, controlled trial of two therapies, endermologie and aminophylline cream, Plast Reconstr Surg 1999; 104:1110-1114; discussion 1115-1117.
183. Lis-Balchin M. Parallel placebo-controlled clinical study of a mixture of herbs sold as a remedy for cellulite. Phytother Res 1999; 13:627-629.
184. Mellinkoff S. Digestive system. Ann Rev Physiol 1957; 19:175-204.
185. Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 1983; 63:484-546.
186. Wurtman J, Wurtman R, Growdon JPH, Lipscomb M, Zeisel S. Carbohydrate-craving in obese people: suppression by treatments affecting serotoninergic neurotransmission. Int J Eat Disord 1981; 1:2-15.
187. Blundell JE. Leshem M. The effect of 5-hydroxytryp-tophan on food intake and on the anorexic action of amphetamine and fenfluramine. J Pharm Pharmacol 1975; 27:31-37.
188. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998; 3:271-280.
189. Weekley LB, Maher RW, Kimbrough TD. Alterations of tryptophan metabolism in a rat strain (Osborne-Mendel) predisposed to obesity. Comp Biochem Physiol A 1982; 72:747-752.
190. Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxyiryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm 1989: 76:109-117.
191. Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992; 56:863-867.
192. Growdon JH. Melamed E. Logue M, Hefti F, Wurtman RJ. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease. Life Sci 1982; 30:827-832.
193. Avraham Y, Bonne O, Berry EM. Behavioral and neurochemical alterations caused by diet restriction- the effect of tyrosine administration in mice. Brain Res 1996; 732:133-144.
194. Hull KM, Maher TJ. L-tyrosine potentiates the anorexia induced by mixed-acting sympathomimetic drugs in hyperphagic rats. J Pharmacol Exp Ther 1990; 255:403-409.
195. Hull KM, Maher TJ. L-tyrosine fails to potentiate several peripheral actions of the sympathomimetics. Pharmacol Biochem Behav 1991; 39:755-759.
196. Hull KM, Maher TJ. Effects of L-tyrosine on mixed-acting sympathomimetic-induced pressor actions. Pharmacol Biochem Behav 1992; 43:1047-1052.
197. Van Itallie TB. Dietary fiber and obesity. Am J Clin Nutr 1978;31:S43-S52.
198. Krotkiewski M. Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects. Br J Nutr 1984; 52:97-105.
199. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984; 8:289-293.
200. Cairella M, Marchini G. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. Clin Ter 1995; 146:269-274.
201. Hylander B. Rossner S. Effects of dietary fiber intake before meals on weight loss and hunger in a weight-reducing club. Acta Med Scand 1983; 213:217-220.
202. Porikos K, Hagamen S. Is fiber satiating? Effects of a high fiber preload on subsequent food intake of normal-weight and obese young men. Appetite 1986; 7:153-162.
203. Witkowska A. Borawska MH. The role of dietary fiber and its preparations in the protection and treatment of overweight. Pol Merkuriusz Lek 1999; 6:224-226.
204. Pasman WJ, Saris WH, Wauters MA, Westerterp-Plantenga MS. Effect of one week of fibre supplementation on hunger and satiety ratings and energy intake. Appetite 1997; 29:77-87.
205. Baron JA, Schori A, Crow B, Carter R, Mann JI. A randomized controlled trial of low carbohydrate and low fat/high fiber diets for weight loss. Am J Public Health 1986; 76:1293-1296.
206. Rigaud D. Ryttig KR, Angel LA, Apfelbaum M. Overweight treated with energy restriction and a dietary fibre supplement: a 6-month randomized, double-blind, placebo-controlled trial. Int J Obes 1990; 14:763-769.
207. Solum TT, Ryttig KR, Solum E. Larsen S. The influence of a high-fibre diet on body weight, serum lipids and blood pressure in slightly overweight persons. A randomized, double-blind, placebo-controlled investigation with diet and fibre tablets (DumoVital). Int J Obes 1987; 11:67-71.
208. Rossner S, von Zweigbergk D, Ohlin A, Ryttig K. Weight reduction with dietary fibre supplements. Results of two double-blind randomized studies. Acta Med Scand 1987; 222:83-88.
209. Gropper SS. Acosta PB. The therapeutic effect of fiber in treating obesity. J Am Coll Nutr 1987; 6: 533-535.
210. Ryttig KR, Tellnes G, Haegh L, Boe E, Fagerthun H. A dietary fibre supplement and weight maintenance after weight reduction: a randomized, double-blind, placebo-controlled long-term trial. Int I Obes 1989; 13:165-171.
211. Quaade F, Vrist E, Astrup A. Dietary fiber added to a very-low caloric diet reduces hunger and alleviates constipation. Ugeskr Laeger 1990; 152:95-98.
212. Pasman WJ, Westerterp-Plantenga MS, Muls E, Van-sant G, Van Ree J, Saris WH. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J Obes Relat Metab Disord 1997;21:548-555.
213. Miller WC, Niederpruem MG, Wallace JP, Lindeman AK. Dietary fat, sugar, and fiber predict body fat content. J Am Diet Assoc 1994; 94:612-615.
214. Alfieri MA, Pomcrleau J, Grace DM, Anderson L. Fiber intake of normal weight, moderately obese and severely obese subjects. Obes Res 1995; 3:541-547.
215. Han LK, Kimura Y, Okuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int J Obes Relat Metab Disord 1999; 23:174-179.
216. Wuolijoki E, Hirvela T, Ylitalo P. Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp Clin Pharmacol 1999; 21:357-361.
217. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999; 53:379-381.
218. Rodgers S, Burnet R, Goss A, et al. Jaw wiring in treatment of obesity. Lancet 1977; 1:1221-1222.
219. Kark AE. Burke M. Gastric reduction for morbid obesity: technique and indications. Br J Surg 1979; 66:756-761.
220. Castelnuovo-Tedesco P, Buchanan DC, Hall HD. Jaw-wiring for obesity. Gen Hosp Psychiatry 1980; 2:156-159.
221. Ross MW, Kalucy RS, Morton JE. Locus of control in obesity: predictors of success in a jaw-wiring programme. Br J Med Psychol 1983; 56:49-56.
222. Ross MW, Goss AN, Kalucy RS. The relationship of panic-fear to anxiety and tension in jaw wiring for obesity. Br J Med Psychol 1984; 57:67-69.
223. Garrow JS, Gardiner GT. Maintenance of weight loss in obese patients after jaw wiring. BMJ (Clin Res Ed) 1981; 282:858-860.
224. Garrow JS, Webster JD, Pearson M, Pacy PJ, Harpin G. Inpatient-outpatient randomized comparison of Cambridge diet versus milk diet in 17 obese women over 24 weeks. Int J Obes 1989; 13:521-529.
225. Pacy PJ, Webster JD. Pearson M, Garrow JS. A cross-sectional cost/benefit audit in a hospital obesity clinic. Hum Nutr Appl Nutr 1987; 41:38-46.
226. Ramsey-Stewart G, Martin L. Jaw wiring in the treatment of morbid obesity. Aust NZ J Surg 1985; 55:163-167.
227. Mathus-Vliegen EM, Tytgat GN. Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span. Br J Surg 1990; 77:76-79.
228. Marshall JB, Schreiber H. Kolozsi W, et al. A prospective, multi-center clinical trial of the Taylor intragastric balloon for the treatment of morbid obesity. Am J Gastroenterol 1990; 85:833-837.
229. Sniegocki G. Comparison of the treatment of obesity by surgical methods and gastric balloon. Wiad Lek 1990; 43:268-274.
230. De Waele B. Reynaert H, Urbain D, Willems G. Intragastric balloons for preoperative weight reduction. Obes Surg 2000; 10:58-60.
231. Vandenplas Y. Bollen P, De Langhe K, Vandemaele K, De Schepper J. Intragastric balloons in adolescents with morbid obesity. Eur J Gastroenterol Hepatol 1999; 11:243-245.
232. Perez-Cuadrado Martinez E, Silva Gonzalez C, Vazquez Dourado R, et al. Complications of the intragastric balloon prosthesis. Rev Esp Enferm Dig 1993; 84:291-295.
233. Butterwegge M, Gethmann U. Ohlenroth G. Ileus in pregnancy induced by a gastric balloon. Zentralbl Gynakol 1993; 115:238-240.
234. Mirich DR, Gray RR, Haber GB. Percutaneous deflation of a gastric balloon: technical note. Cardiovasc Intervent Radiol 1989; 12:164-165.
235. Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc 1989; 35:381- 385.
236. Geliebter A, Melton PM. Gage D, McCray RS. Hashim SA. Gastric balloon to treat obesity: a double-blind study in nondieting subjects. Am J Clin Nutr 1990; 51:584-588.
237. Mathus-Vliegen EM, Tytgat GN, Veldhuyzen-Offer-mans EA. Intragastric balloon in the treatment of super-morbid obesit. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon. Gastroenterology 1990; 99:362-369.
238. Geliebter A, Melton PM, McCray RS, et al. Clinical trial of silicone-rubber gastric balloon to treat obesity. Int J Obes 1991; 15:259-266.
239. Krakamp B, Leidig P, Gehmlich D. Paul A. Stomach volume reduction balloon for weight loss: what is the justification for this controversial method? Zentralbl Chir 1997; 122:349-356.
240. Kirby DF, Wade JB, Mills PR, et al. A prospective assessment of the Garren-Edwards gastric bubble and bariatric surgery in the treatment of morbid obesity. Am Surg 1990; 56:575-580.
241. Pasquali R. Besteghi L, Casimirri F, et al. Mechanisms of action of the intragastric balloon in obesity: effects on hunger and satiety. Appetite 1990; 15:3-11.
242. Durrans D, Taylor TV, Holt S. Intragastric device for weight loss. Effect on energy intake in dogs. Dig Dis Sci 1991; 36:893-896.
243. Northway MG, Geisinger KR, Gilliam JH, MacLean DB. Weight loss induced by gastric implant in rats. Effects of capsaicin sensory denervation. Dig Dis Sci 1992; 37:1051-1056.
244. Melton PM, Kissileff HR, Pi-Sunyer FX. Cholecysto-kinin (CCK-8) affects gastric pressure and ratings of hunger and fullness in women. Am J Physiol 1992; 263:R452-R456.
245. Boosalis MG, Gemayel N, Lee A, Bray GA, Laine L, Cohen H. Cholecystokinin and satiety: effect of hypothalamic obesity and gastric bubble insertion. Am J Physiol 1992; 262:R241-R244.
246. Rigaud D. Trostler N, Rozen R, Vallot T, Apfelbaum M. Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord 1995; 19:489-495.
247. Tosetti C, Corinaldesi R, Stanghellini V, et al. Gastric emptying of solids in morbid obesity. Int J Obes Relat Metab Disord 1996; 20:200-205.
248. Geliebter A, Schachter S, Lohmann-Walter C, Feldman H, Hashim SA. Reduced stomach capacity in obese subjects after dieting. Am J Clin Nutr 1996; 63:170-173.
249. Cigaina V. Pinato G. Rigo V, et al. Gastric peristalsis control by mono situ electrical stimulation: a preliminary study. Obes Surg 1996; 6:247-249.
250. Cigaina V, Saggioro A, Rigo V, Pinato G, Ischai S. Long-term effects of gastric pacing to reduce feed intake in swine. Obes Surg 1996; 6:250-253.
251. Cigaina V. The long-term effects of gastric pacing on an obese young woman. Obes Surg 1996; 6:312-313.
252. Cigaina V. Gastric myo-electrical pacing as therapy for morbid obesity: preliminary results. Obes Surg 1999; 9:333-334.
253. Simpson GK. Farquhar DL. Carr P, et al. Intermittent protein-sparing fasting with abdominal belting. Int J Obes 1986; 10:247-254.
254. Garrow JS. Morbid obesity: medical or surgical treatment? The case for medical treatment. Int J Obes 1987; 11:1-4.
255. Garrow JS. Treatment of morbid obesity by nonsurgical means: diet, drugs, behavior modification, exercise. Gastroenterol Clin North Am 1987; 16:443-449.
256. Garrow JS. Is it possible to prevent obesity? Infusions-therapie 1990; 17:28-31.
257. Garrow JS. The management of obesity. Another view. Int J Obes Relat Metab Disord 1992; 16(supp) 2):S59-S63.
258. Kirsch I, Montgomery G, Sapirstein G. Hypnosis as an adjunct to cognitive-behavioral psychotherapy: a metaanalysis. J Consult Clin Psychol 1995; 63:214-220.
259. Kirsch I. Hypnotic enhancement of cognitive-behavioral weight loss treatments-another meta-reanalysis. J Consult Clin Psychol 1996; 64:517-519.
260. Allison DB, Faith MS. Hypnosis as an adjunct to cognitive-behavioral psychotherapy for obesity: a meta-analytic reappraisal. J Consult Clin Psychol 1996;64:513-516.
261. Johnson DL, Karkut RT. Participation in multicom-ponent hypnosis treatment programs for women’s weight loss with and without overt aversion. Psychol Rep 1996; 79:659-668.
262. Johnson DL. Weight loss for women: studies of smokers and nonsmokers using hypnosis and multicompo-nent treatments with and without overt aversion. Psychol Rep 1997; 80:931-933.
263. Stradling J, Roberts D, Wilson A, Lovelock F. Controlled trial of hypnotherapy for weight loss in patients with obstructive sleep apnoea. Int J Obes Relat Metab Disord 1998; 22:278-281.
264. Haber CH, Nitkin R, Shenker IR. Adverse reactions to hypnotherapy in obese adolescents: a developmental viewpoint. Psychiatr Q 1979; 51:55-63.
265. Schoenberger NE. Research on hypnosis as an adjunct to cognitive-behavioral psychotherapy. Int J Clin Exp Hypn 2000; 48:154-169.
266. Cole AD. Bond N.W. Olfactory aversion conditioning and overeating: a review and some data. Percept Mot Skills 1983; 57:667-678.
267. Mok MS, Parker LN, Voina S, Bray GA. Treatment of obesity by acupuncture. Am J Clin Nutr 1976; 29:832-835.
268. Richards D, Marley J. Stimulation of auricular acupuncture points in weight loss. Aust Fam Physician 1998; 27(suppl 2):S73-S77.
269. Allison DB. Kreibich K. Heshka S, Heymsfield SB. A randomised placebo-controlled clinical trial of an acupressure device for weight loss. Int J Obes Relat Metab Disord 1995; 19:653-658.